SLC7A11 and ovarian carcinoma: Thus, SLC7A11 expression is inconsistent in paclitaxel- and cisplatin-resistant ovarian cancer since SLC7A11 expression is high in cisplatin-resistant but low in paclitaxel-resistant ovarian cancer, suggesting that SLC7A11 plays distinct roles in these two cases of chemotherapy resistance, possibly due to its modulation of different signaling pathways.